AbbVie Inc

ABBV: XNYS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|w!LOCK|B&bLOCK|Rb?ccd

AbbVie: Apogee Acquisition Brings Significant Weight to Immunology Pipeline

On June 22, AbbVie announced an agreement to acquire immunology-focused biopharma firm Apogee Therapeutics for $10.1 billion (net of cash acquired). The deal is expected to close in the third quarter. AbbVie shares rose 6%.

Sponsor Center